Rheumatology in 2006: Crossroads or crisis?

Bulletin of the NYU Hospital for Joint Diseases

Volumn 64, Issue 1-2, 2006, Pages 9-11

  Pisetsky, David S ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

BIOMEDICINE; BONE NECROSIS; CLINICAL RESEARCH; CONFERENCE PAPER; DRUG RESEARCH; FIBROMYALGIA; HUMAN; MEDICAL INFORMATICS; OSTEOARTHRITIS; OUTCOMES RESEARCH; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK BENEFIT ANALYSIS;

BIOMEDICAL RESEARCH; CONGRESSES; HUMANS; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 33750291404     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (8)

1. Boers M. Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard? Arthritis Rheum. 2003;48:1481-3.
2. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials for American College of Rheumatology criteria for remission. J Rheumatol. 2003;30:1135-7.
3. Aletha D, Ward WM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis. Defining criteria for disease activity states. Arthritis Rheum. 2005;52:2625-36.
4. Snyderman R, Langheier J. Prospective health care: the second transformation of medicine. Genome Biol. 2006;7:104.
5. Pincus P, Yazici Y, Bergman M. Saving time and improving care with multidimensional health assessment questionnaire: 10 practical considerations. J Rheumatol. 2006;33:448-54.
6. Ott S. Long-term safety of bisphosphonates. J Clin Endocrin Metab. 2005;90:1897-9.
7. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrin Metab. 2005;90:1294-1301.
8. Costenbader KH, Karlson EW, Gall V, et al. Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. Arthritis Rheum. 2005;53:718-23.